KRAS & Lung Cancer

Currently, treatment strategies for KRAS-mutant non-small cell lung cancer (NSCLC) are limited. Fortunately, over the past few years, research has focused on creating two new treatment options. One is the creation of a class of drugs called targeted therapies. These new drugs have been created to specifically stop the growth of KRAS-mutant driven cancers. The other treatment option is called immunotherapy. Immunotherapy is a type of treatment that uses the patient’s own immune system to fight the cancer.

The goal of the Dream Team is to optimize and combine targeted therapy with immunotherapy in order to radically improve the outcomes for patients with KRAS-mutant NSCLC.